Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-02-13
2007-02-13
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S557000, C554S225000, C562S493000
Reexamination Certificate
active
10194247
ABSTRACT:
The compound of the formula (I):wherein R1is alkyl substituted by fluorine(s);R2is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4,in which R3, R4is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3and R4, taken together a saturated heterocyclic ring or amino acid residues;and non-toxic salts thereof and acid addition salts thereof.The compounds of the present invention of the formula (I) and the compounds of the formula (X):wherein n is 0 or 1,R11is hydrogen and chlorine,R5is R7—CH2— or R8, orR5and R11, taken together is alkylidene;R6is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10,in which R9, R10is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl-substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R9and R10, taken together a saturated heterocyclic ring or amino acid residues, R7is (i) F—(CH2)m— or F3C—CH2—, (ii) alkyl substituted by chlorine, (iii) alkyl substituted by alkoxy, cycloalkyl, phenyl, phenoxy;R8is alkyl, alkenyl, alkoxy, alkylthio, cycloalkyl, phenyl, phenoxy;non-toxic salts and acid addition salts thereof are useful for prevention and/or treatment for neurodegenerarive disease (Alzheimer's disease etc.) and neuronal dysfunction by stroke or traumic injury (Multiple sclerosis etc.) etc.
REFERENCES:
patent: 2868691 (1959-01-01), Porush et al.
patent: 3095355 (1963-06-01), Abramson et al.
patent: 3325361 (1967-06-01), Meunier
patent: 3487956 (1970-01-01), Schaefer
patent: 3701729 (1972-10-01), Fischer et al.
patent: 3847956 (1974-11-01), Silbert et al.
patent: 3932285 (1976-01-01), Ceprini et al.
patent: 4025649 (1977-05-01), Taillandier et al.
patent: 4127604 (1978-11-01), Chignac et al.
patent: 4129599 (1978-12-01), Escher et al.
patent: 4377533 (1983-03-01), Bouisset et al.
patent: 4900553 (1990-02-01), Silver et al.
patent: 4923696 (1990-05-01), Appel et al.
patent: 4997929 (1991-03-01), Collins et al.
patent: 5011914 (1991-04-01), Collins et al.
patent: 5017375 (1991-05-01), Appel et al.
patent: 5021398 (1991-06-01), Sharma et al.
patent: 5141856 (1992-08-01), Collins et al.
patent: 5166317 (1992-11-01), Wallace et al.
patent: 5169764 (1992-12-01), Shooter et al.
patent: 5180820 (1993-01-01), Barde et al.
patent: 5202120 (1993-04-01), Silver et al.
patent: 5215969 (1993-06-01), Springer et al.
patent: 5229365 (1993-07-01), Polak et al.
patent: 5229500 (1993-07-01), Barde et al.
patent: 5235043 (1993-08-01), Collins et al.
patent: 5332672 (1994-07-01), Conover et al.
patent: 5340808 (1994-08-01), Jaen et al.
patent: 5342942 (1994-08-01), Jaen et al.
patent: 5349056 (1994-09-01), Panayotatos
patent: 5360740 (1994-11-01), Ip et al.
patent: 5364769 (1994-11-01), Rosenthal
patent: 5387520 (1995-02-01), LoPresti et al.
patent: 5426177 (1995-06-01), Davis et al.
patent: 5438121 (1995-08-01), Barde et al.
patent: 5441937 (1995-08-01), Wallace et al.
patent: 5453361 (1995-09-01), Yancopoulos
patent: 5475088 (1995-12-01), Perez-Polo
patent: 5504197 (1996-04-01), Schubert et al.
patent: 5514658 (1996-05-01), Santos Benito et al.
patent: 5672746 (1997-09-01), Nau et al.
patent: 5712160 (1998-01-01), Perez-Polo
patent: 5780587 (1998-07-01), Potter
patent: 5786380 (1998-07-01), Nau et al.
patent: 5846935 (1998-12-01), Panayotatos
patent: 5869463 (1999-02-01), Major et al.
patent: 0252736 (1988-01-01), None
patent: 0 504 069 (1992-03-01), None
patent: 0 632 008 (1995-01-01), None
patent: 2 599 737 (1987-12-01), None
patent: 56-80116 (1981-07-01), None
patent: 59-67266 (1984-04-01), None
patent: 1 135740 (1989-05-01), None
patent: 6116200 (1994-04-01), None
patent: 6 188152 (1994-07-01), None
patent: WO 91/04316 (1991-04-01), None
patent: WO 94/06743 (1994-03-01), None
patent: WO 94/12608 (1994-06-01), None
Scientific American, pp. 44-52, Apr. 1989.
J. Anat., 106 471 (1970).
Dev. Biol. 72, 381 (1979).
Adv. Cell, Neurobiol., 2, 249 (1981).
Science, 237, 642 (1987).
Brain Res., 481, 190 (1989).
Ibid, 547, 223 (1991).
Cytobios, 61, 133 (1990).
Biochem, Biophys. Res., Commun., 136, 57 (1986).
Brain Res 560, 76 (1991).
Neuron, 3, 275 (1989).
J. Neurosci, Res. 25, 431 (1990).
FEBS Lett., 292, 171 (1991).
J. Neurol. Sci., 112, 68 (1992).
Proc. Natl. Acad. Sci. USA, 82, 4245 (1985).
Brain Res. Reviews, 16, 83 (1991).
TIPS, 12, 383 (1991).
Proc. Natl. Acad. Sci. USA, 87, 9020 (1990).
Brain Res. 533, 315 (1990).
Neurology, 40, 33 (1990).
Nikkei Sci, J., 9, 52 (1991).
Neuropharmacology, 24(5), 427-435 (1985).
Neuropharmacology, 25, 617 (1986).
Brain Res., 459, 131 (1988).
Brain Res. 554, 223 (1991).
Neurochem. Res., 17, 327, (1992).
Science, 250, 279 (1990).
Neurobiol. Aging, 13, 239 (1992).
Chemical Abstracts, vol. 64, No. 7, Mar. 28, 1966.
Chemical Abstracts. vol. 82, No. 25, Jun. 23, 1975.
Chemical Abstracts, vol. 114, No. 1, Jan. 7, 1991.
Sodium Valproate in the Treatment of Behavioral Disturbance in Dementia, Journal of Geriatric Psychiatry and Neurology, vol. 6, Oct.-Dec. 1993, pp. 205-209.
Aaronson, S.A., “Growth Factors and Cancer,”Science, 254: 1146-1153 (1991).
Atkinson, R.S., et al, “Intramolecular Reactions of N-Nitrenes with Alkenes,”J. Chem. Soc., Perkin Trans, 1:1905-12 (1984).
Atkinson, R.S., et al., “Intramolecular Reactions of N-Nitrenes: Description of the Transition State Geometry For Addition to Alkenes,”J. Chem. Soc., Perkins Trans.1:1135-45 (1987).
Bailey et al., “Serotonin-Mediated Endocytosis of apCAM: An Early Step of Learning-Related Synaptic Growth inAplysia,” Science, 256:645-649 (1992).
Barton, H., et al., “Photochemical Degradation of Barbituric Acid Derivatives,”Pharmazie, 38:630-1 (1983).
Baxter, G.P., “Thirty-sixth Annual Report of the Committee on Atomic Weights Determinations Published During 1929,”J. Am. Chem. Soc., 52:1281-1283 (1930).
Bormann, Joachim et al, “Patch-clamp study of λ-aminobutyric acid receptor CL−channels in cultured astrocytes,”Proc. Natl. Acad. Sci. USA, vol. 85, pp. 9336-9340, Dec. 1988.
Breen et al., “Differentiation-Dependent Sialylation of Individual Neural Cell Adhesion Molecule Polypeptides During Postnatal Development,”J. Neurochem, 50:712-716 (1988).
Butters, N., “Alcoholic Korsakoff's Syndrome: An Update,”Seminar Neurology, 4:226-244 (1984).
Bojic, et al., “Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic center,”European Journal of Pharmacology, 354 (1998) 289-299.
Borstlap, C, “2-alkylalkanoic Acids: Relation Between Structure and Sensitivity Towards Water Hardness,”Chem. Phys. Chem. Anwendungstech. Grenzflaechenaktiven Stoffe, Ber. Int. Knogr., 6th, 1:91-9 (1973).
Breusch, F.L., et al., “Isomeric Series of the Di-N-Alkylacetic Acids C23H46O2,”Second Chemical Institute of the University of Istanbul, Series C., 33:39-42 (1968).
Cairns et al, “Astrocytosis βA4-protein deposition and paired helical filament formation in Alzheimer's disease,”J. Neurol. Sci., 112:68 (1992).
Chapman, A.G., et al., “Acute Anticonvulsant Activity of Structural Analogues of Valproic Acid and Changes in Brain Gaba and Aspartate Content,”Life Sciences, 32:2023-2031 (1983).
Chernoff and Golden, “Hyperthermia-Induced Exencephaly in Mice: Effect of Multiple Exposures,”Teratology, 37:37-42 (1988).
Ciardi, A., et al, “The involvement of the cerebral cortex in human immunodefeciency virus encephalopathy: a morphological an immunohistochemical study,”Acta neuropathologica, 81:51-59 (1990).
Communication From Australian Patent Office Concerning Section 27(1) Filing by Ono Pharmaceutical Comp
Kishimoto Kazuo
Ohno Hiroyuki
Ohuchida Shuichi
Tateishi Narito
Chong Yong S.
Ono Pharmaceutical Co. Ltd.
Wang Shengjun
LandOfFree
Pentanoic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pentanoic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pentanoic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891365